Sugi Predict

Sugi Predict / Compounds / SCHEMBL2592748

SCHEMBL2592748

SCHEMBL2592748

Cc1c[nH]c2cccc(C(=O)O)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 4/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ PARP1 P09874 1/20 0.45
▸ MYC P01106 1/20 0.43
▸ GPR84 Q9NQS5 1/20 0.43
▸ NR4A2 P43354 1/20 0.43
▸ NAPRT Q6XQN6 1/20 0.43
▸ NOTUM Q6P988 2/20 0.42
▸ CTNNB1 P35222 1/20 0.42
▸ WNT3A P56704 1/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ DNMT1 P26358 1/20 0.41
▸ RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3995494 0.86 GPR84 (0.51) HSD17B10ALDH1A1KDM4EHPGDMYC
SCHEMBL2588267 0.84 ALDH1A1 (0.50) ALDH1A1PARP1GPR84NR4A2CTNNB1
SCHEMBL29926543 0.84 ALDH1A1 (0.50) ALDH1A1PARP1GPR84NR4A2CTNNB1
SCHEMBL1223596 0.81 NR4A2 (0.61) HSD17B10ALDH1A1KDM4ENR4A2POLB
SCHEMBL29886596 0.81 NR4A2 (0.61) HSD17B10ALDH1A1KDM4ENR4A2POLB
SCHEMBL15836985 0.79 TSHR (0.54) HSD17B10ALDH1A1KDM4ENR4A2KMT2A
SCHEMBL10411714 0.79 PARP1 (0.45) HSD17B10ALDH1A1KDM4EPARP1GPR84
SCHEMBL2309708 0.78 HSD17B10 (0.55) HSD17B10ALDH1A1KDM4EHPGDGPR84
SCHEMBL27819612 0.78 PARP1 (0.42) HSD17B10ALDH1A1KDM4EHPGDPARP1
SCHEMBL3960635 0.76 GPR84 (0.49) ALDH1A1KDM4EGPR84NR4A2CTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243160-A1 INDOLE DERIVATIVES FOR TARGETING AUTOPHAGY Automera PTE. LTD (SG) 2025-07-31 — — US disclosed
CN-108137542-B Pyridone dicarboxamides as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2023-10-27 — — CN disclosed
US-10927080-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-02-23 — — US disclosed
US-10428026-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-10-01 — — US disclosed
US-20180258044-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-09-13 — — US disclosed
EP-3344615-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) 2018-07-11 — — EP disclosed
CN-108137542-A Pyridone diformamide as bromine structural domain inhibitor 葛兰素史克知识产权第二有限公司 2018-06-08 — — CN disclosed
EP-3246027-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER GlaxoSmithKline LLC (US) 2017-11-22 — — EP disclosed
EP-2772484-B1 BICYCLIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC (JP) 2017-06-28 — — EP disclosed
US-9649307-B2 Indoles GLAXOSMITHKLINE LLC (US) 2017-05-16 — — US disclosed
EP-2773754-A1 METHOD OF TREATMENT Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-09-10 — — EP disclosed
US-20140249151-A1 BICYCLIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC. (JP) 2014-09-04 — — US disclosed
EP-2772484-A1 BICYCLIC HETEROCYCLIC COMPOUND Astellas Pharma Inc. (JP) 2014-09-03 — — EP disclosed
CN-103917524-A Bicyclic heterocyclic compound ASTELLAS PHARMA INC 2014-07-09 — — CN disclosed
US-20130345200-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2013-12-26 — — US disclosed
US-8536179-B2 Indoles GLAXOSMITHKLINE LLC (US) 2013-09-17 — — US disclosed
WO-2013067296-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) 2013-05-10 — — WO disclosed
EP-2566327-A1 INDOLES GlaxoSmithKline LLC (US) 2013-03-13 — — EP disclosed
US-20130053397-A1 INDOLES GLAXOSMITHKLINE LLC 2013-02-28 — — US disclosed
WO-2011140324-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249151-A1 BICYCLIC HETEROCYCLIC COMPOUND HSD11B1, HSD17B11, HSD17B1 HSD17B10 13/4885ALDH1A1 349/4885KDM4E 3611/4885
US-10428026-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors BRD4, BRD3, BRDT HSD17B10 1481/4885ALDH1A1 1362/4885KDM4E 426/4885
US-20250243160-A1 INDOLE DERIVATIVES FOR TARGETING AUTOPHAGY SQSTM1, ATG7, BECN1 HSD17B10 1219/4885ALDH1A1 3383/4885KDM4E 3268/4885
US-20180258044-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT HSD17B10 1481/4885ALDH1A1 1362/4885KDM4E 426/4885
US-20130345200-A1 INDOLES IDO1, IDO2, INMT HSD17B10 638/4885ALDH1A1 38/4885KDM4E 1312/4885
US-10927080-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors BRD4, BRD3, BRDT HSD17B10 1481/4885ALDH1A1 1362/4885KDM4E 426/4885
US-20130053397-A1 INDOLES IDO1, IDO2, INMT HSD17B10 652/4885ALDH1A1 45/4885KDM4E 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.